Systems for inhibiting heterotopic ossification

A guide set for treating a targeted volume of muscle tissue to inhibit heterotopic ossification (HO), the guide set comprising:

• a guide member having a first surface shaped to compliment an intraoperatively exposed surface of the targeted volume of muscle tissue within a larger volume of muscle tissue that has been identified as being susceptible to HO,
• wherein the guide member is configured for placement of the first surface onto the intraoperatively exposed surface of the targeted volume of muscle tissue,
• wherein the guide member has at least a first opening and a second opening therethrough,
• wherein each of the first opening and the second opening is sized to receive and direct an intramuscular needle therethrough,
• wherein the first opening is positioned such that when the intramuscular needle is inserted into the first opening, a distal end of the intramuscular needle is positioned at a first delivery location suitable for delivery of a first aliquot of a neuromuscular inhibitor,
• wherein the second opening is positioned such that when the intramuscular needle is inserted into the second opening, the distal end of the intramuscular needle is positioned at a second delivery location suitable for delivery of a second aliquot of the neuromuscular inhibitor;
• wherein when the first aliquot and the second aliquot are delivered at the first delivery location and at the second delivery location via the intramuscular needle, a spacing of the first delivery location and the second delivery location in conjunction with a respective volume of each one of the first aliquot and the second aliquot results in a therapeutic distribution of a therapeutic dose of the neuromuscular inhibitor within the targeted volume of muscle tissue that is sufficient to prevent formation of an HO lesion but insufficient to induce paralysis of the larger volume of muscle tissue;
• and
• wherein the therapeutic distribution of the therapeutic dose of the neuromuscular inhibitor within the targeted volume of muscle tissue is configured to reduce bone loss.

A system for treating a targeted volume of muscle tissue to inhibit heterotopic ossification (HO), the system comprising:

• a delivery device comprising a needle and a reservoir containing a neuromuscular inhibitor, wherein the needle is sized for intramuscular injection of the neuromuscular inhibitor and wherein the delivery device is configured to eject predetermined aliquots of a therapeutic dose of the neuromuscular inhibitor through the needle;
• and
• an injection guide assembly comprising a first guide member and a device body having a receiving region configured to receive the first guide member to form the injection guide assembly, wherein:
• the first guide member defines at least a first guide hole and a second guide hole offset from the first guide hole;
• each of the first guide hole and the second guide hole is configured to guide the needle;
• the device body has a first surface shaped to compliment the targeted volume of muscle tissue within a larger volume of muscle tissue that has been identified as being susceptible to HO;
• the first guide hole is positioned relative to the device body such that when the needle is inserted through the first guide hole, a distal end of the needle is positioned at a first delivery location suitable for delivery of a first aliquot of the predetermined aliquots;
• the second guide hole is positioned relative to the device body such that when the needle is inserted through the second guide hole, the distal end of the needle is positioned at a second delivery location suitable for delivery of a second aliquot of the predetermined aliquots;
• and
• a spacing of the first delivery location and the second delivery location in conjunction with a respective volume of each one of the first aliquot of the predetermined aliquots and the second aliquot of the predetermined aliquots results in a therapeutic distribution of the therapeutic dose of the neuromuscular inhibitor within the targeted volume of muscle tissue that is sufficient to prevent formation of an HO lesion and to reduce bone loss but insufficient to induce paralysis of the larger volume of muscle tissue.

An injection guide assembly for treating a targeted volume of muscle tissue to inhibit heterotopic ossification (HO), the injection guide assembly comprising:

• a guide member and a device body having a receiving region configured to receive the guide member to form the injection guide assembly, wherein:
• the guide member is configured as a unitary structure;
• the device body has a first surface shaped to compliment the targeted volume of muscle tissue within a larger volume of muscle tissue that has been identified as being susceptible to HO,
• the guide member defines at least a first guide hole and a second guide hole offset from the first guide hole,
• each of the first guide hole and the second guide hole is sized to receive and direct an intramuscular needle therethrough,
• the first guide hole is positioned relative to the device body such that when the intramuscular needle is inserted into the first guide hole, a distal end of the intramuscular needle is positioned at a first delivery location suitable for delivery of a first aliquot of a neuromuscular inhibitor,
• the second guide hole is positioned relative to the device body such that when the intramuscular needle is inserted into the second guide hole, the distal end of the intramuscular needle is positioned at a second delivery location suitable for delivery of a second aliquot of the neuromuscular inhibitor;
• and
• when the first aliquot and the second aliquot are delivered at the first delivery location and at the second delivery location via the intramuscular needle, a spacing of the first delivery location and the second delivery location in conjunction with a respective volume of each one of the first aliquot and the second aliquot results in a therapeutic distribution of a therapeutic dose of the neuromuscular inhibitor within the targeted volume of muscle tissue that is sufficient to prevent formation of an HO lesion and to reduce bone loss but insufficient to induce paralysis of the larger volume of muscle tissue.